In retroviral vector-mediated gene transfer, transduction efficiency can be hampered by inhibitory molecules derived from the culture fluid of virus producer cell lines. To remove these inhibitory molecules to enable better gene transduction, we had previously developed a transduction method using a fibronectin fragment-coated vessel (i.e., the RetroNectin-bound virus transduction method). In the present study, we developed a method that combined RetroNectin-bound virus transduction with low-temperature shaking and applied this method in manufacturing autologous retroviral-engineered T cells for adoptive transfer gene therapy in a large-scale closed system. Retroviral vector was preloaded into a RetroNectin-coated bag and incubated at 4uC f...
Though both low-speed centrifugation and the use of fibronectin (Retronectin) fragments increase gen...
Recently, we constructed retroviral vector particles derived from spleen necrosis virus (SNV) that d...
BACKGROUND: Because gene therapy of the future will primarily take an in vivo approach, a number of ...
In retroviral vector-mediated gene transfer, transduction efficiency can be hampered by inhibitory m...
The transfer of T-cell receptor (TCR) genes into primary human T-cells to endow their specificity to...
Chimeric antigen receptors (CARs) are genetically delivered fusion molecules that elicit T-cell acti...
Retroviral vector-mediated gene transfer into endothelial cells is relatively inefficient with trans...
A new procedure is described for the generation of high-titer, helper-free retrovirus vectors employ...
Retroviral vectors derived from the Moloney murine leukemia virus have been used in successful and p...
Overview summary Flow-through transduction provides a means by which high rates of gene transfer can...
Replication-defective retroviruses are frequently used as gene carriers for gene transfer into mamma...
Retroviral vectors have become a standard tool for gene transfer technology. Compared with other gen...
Background For our clinical immunogene therapy study for the treatment of renal cell carcinoma (RCC)...
Recombinant retroviruses (gammaretro-, lenti- and foamy-viral vectors) are used for gene therapy as ...
poster abstractReplication incompetent retroviral vectors are currently used in phase 1 clinical tri...
Though both low-speed centrifugation and the use of fibronectin (Retronectin) fragments increase gen...
Recently, we constructed retroviral vector particles derived from spleen necrosis virus (SNV) that d...
BACKGROUND: Because gene therapy of the future will primarily take an in vivo approach, a number of ...
In retroviral vector-mediated gene transfer, transduction efficiency can be hampered by inhibitory m...
The transfer of T-cell receptor (TCR) genes into primary human T-cells to endow their specificity to...
Chimeric antigen receptors (CARs) are genetically delivered fusion molecules that elicit T-cell acti...
Retroviral vector-mediated gene transfer into endothelial cells is relatively inefficient with trans...
A new procedure is described for the generation of high-titer, helper-free retrovirus vectors employ...
Retroviral vectors derived from the Moloney murine leukemia virus have been used in successful and p...
Overview summary Flow-through transduction provides a means by which high rates of gene transfer can...
Replication-defective retroviruses are frequently used as gene carriers for gene transfer into mamma...
Retroviral vectors have become a standard tool for gene transfer technology. Compared with other gen...
Background For our clinical immunogene therapy study for the treatment of renal cell carcinoma (RCC)...
Recombinant retroviruses (gammaretro-, lenti- and foamy-viral vectors) are used for gene therapy as ...
poster abstractReplication incompetent retroviral vectors are currently used in phase 1 clinical tri...
Though both low-speed centrifugation and the use of fibronectin (Retronectin) fragments increase gen...
Recently, we constructed retroviral vector particles derived from spleen necrosis virus (SNV) that d...
BACKGROUND: Because gene therapy of the future will primarily take an in vivo approach, a number of ...